WO2002007757A3 - Prevention and treatment of sexual arousal disorders - Google Patents

Prevention and treatment of sexual arousal disorders Download PDF

Info

Publication number
WO2002007757A3
WO2002007757A3 PCT/US2001/022970 US0122970W WO0207757A3 WO 2002007757 A3 WO2002007757 A3 WO 2002007757A3 US 0122970 W US0122970 W US 0122970W WO 0207757 A3 WO0207757 A3 WO 0207757A3
Authority
WO
WIPO (PCT)
Prior art keywords
sexual arousal
bdnf
bfgf
vegf
preventing
Prior art date
Application number
PCT/US2001/022970
Other languages
French (fr)
Other versions
WO2002007757A2 (en
WO2002007757A9 (en
Inventor
Tom F Lue
Ching-Shwun Lin
Yuet W Kan
Original Assignee
Tom F Lue
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tom F Lue filed Critical Tom F Lue
Priority to AU2001278981A priority Critical patent/AU2001278981A1/en
Priority to EP01957212A priority patent/EP1365794A2/en
Publication of WO2002007757A2 publication Critical patent/WO2002007757A2/en
Publication of WO2002007757A3 publication Critical patent/WO2002007757A3/en
Publication of WO2002007757A9 publication Critical patent/WO2002007757A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

This invention relates generally to the field of urology. In particular, the invention provides a method for preventing or treating male erectile dysfunction or female sexual arousal disorder, which method comprises administering an effective amount of vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), basic fibroblast growth factor (bFGF), or a functional derivative or fragment thereof, or a nucleic acid encoding said VEGF, BDNF or bFGF, or functional derivative or fragment thereof, or an agent that enhances production and/or erection or sexual arousal stimulating function of said VEGF or BDNF or bFGF to a mammal, wherein such prevention or treatment is desirable, thereby preventing or treating said male erectile dysfunction of female sexual arousal disorder in said mammal. Combinations, combinatorial methods and kits for preventing or treating male erectile dysfunction or female sexual arousal disorder are also provided.
PCT/US2001/022970 2000-07-21 2001-07-19 Prevention and treatment of sexual arousal disorders WO2002007757A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001278981A AU2001278981A1 (en) 2000-07-21 2001-07-19 Prevention and treatment of sexual arousal disorders
EP01957212A EP1365794A2 (en) 2000-07-21 2001-07-19 Prevention and treatment of sexual arousal disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22003100P 2000-07-21 2000-07-21
US60/220,031 2000-07-21

Publications (3)

Publication Number Publication Date
WO2002007757A2 WO2002007757A2 (en) 2002-01-31
WO2002007757A3 true WO2002007757A3 (en) 2003-09-18
WO2002007757A9 WO2002007757A9 (en) 2004-05-06

Family

ID=22821763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022970 WO2002007757A2 (en) 2000-07-21 2001-07-19 Prevention and treatment of sexual arousal disorders

Country Status (4)

Country Link
US (2) US6852323B2 (en)
EP (1) EP1365794A2 (en)
AU (1) AU2001278981A1 (en)
WO (1) WO2002007757A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223957A4 (en) * 1999-10-01 2003-05-14 Univ Duke A method of treating erectile dysfunction
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
PL2442651T3 (en) * 2009-06-19 2015-12-31 Teva Pharma Treatment of multiple sclerosis with laquinimod
KR20160148050A (en) * 2009-07-30 2016-12-23 테바 파마슈티컬 인더스트리즈 리미티드 Treatment of crohn's disease with laquinimod
ES2586843T3 (en) 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Treatment of disorders related to BDNF using laquinimod
PE20130496A1 (en) * 2010-03-03 2013-05-08 Teva Pharma LUPUS ARTHRITIS TREATMENT USING LAQUINIMOD
MX337614B (en) * 2010-03-03 2016-03-10 Teva Pharma Treatment of lupus nephritis using laquinimod.
CN105796556A (en) * 2010-03-03 2016-07-27 泰华制药工业有限公司 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2014004420A (en) 2011-10-12 2014-07-09 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod.
TW201345527A (en) 2012-02-03 2013-11-16 Teva Pharma Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFα therapy
TW201400117A (en) 2012-06-05 2014-01-01 Teva Pharma Treatment of ocular inflammatory disease using laquinimod
TW201410244A (en) 2012-08-13 2014-03-16 Teva Pharma Laquinimod for treatment of GABA mediated disorders
WO2016112049A1 (en) 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Angiogenic treatment of ischemic heart disease
CA2976675A1 (en) 2015-02-16 2016-08-25 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043029A1 (en) * 1999-01-21 2000-07-27 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
WO2001024809A1 (en) * 1999-10-01 2001-04-12 Duke University A method of treating erectile dysfunction
WO2001068125A2 (en) * 2000-03-10 2001-09-20 Chiron Corporation Methods and compositions for the treatment and prevention of erectile dysfunction

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5026839A (en) 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
SE463851B (en) 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
US5188943A (en) 1988-11-07 1993-02-23 Synergen, Inc. Method of producing high molecular weight human fibroblast growth factors
US5130418A (en) 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5270053A (en) 1990-04-03 1993-12-14 Ciba-Geigy Corp. Parenterally administerable liposome formulation comprising synthetic lipid
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
US5235043A (en) 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
AU654302B2 (en) * 1990-09-25 1994-11-03 Genentech Inc. Novel neurothrophic factor
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5206354A (en) 1990-11-23 1993-04-27 American Cyanamid Company Dna sequence encoding active fragment of fibroblast growth factor, hbf-2
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
DE4221256C2 (en) 1992-06-26 1997-07-10 Lancaster Group Ag Galenic composition for topical use
US5646181A (en) 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
JPH06247842A (en) 1993-02-23 1994-09-06 Green Cross Corp:The Production of liposome composition
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
CA2188385C (en) * 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
ATE278794T1 (en) 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
WO1997003635A2 (en) 1995-07-17 1997-02-06 Board Of Regents, The University Of Texas System p16 EXPRESSION CONSTRUCTS AND THEIR APPLICATION IN CANCER THERAPY
US5941868A (en) 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois Materials and methods for making improved liposome compositions
JPH10212241A (en) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Preparation stably containing bdnf
US6133026A (en) 1996-05-31 2000-10-17 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
JP2002508765A (en) 1997-06-23 2002-03-19 アルザ コーポレイション Liposome-encapsulated polynucleotide compositions and methods
US6221646B1 (en) 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
SE9703226D0 (en) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5891915A (en) 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor
US6031002A (en) 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
FI991197A0 (en) 1999-05-27 1999-05-27 Mart Saarma Neurotropic factors in the treatment of pelvic peripheral dysfunction
US6436944B1 (en) * 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043029A1 (en) * 1999-01-21 2000-07-27 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
WO2001024809A1 (en) * 1999-10-01 2001-04-12 Duke University A method of treating erectile dysfunction
WO2001068125A2 (en) * 2000-03-10 2001-09-20 Chiron Corporation Methods and compositions for the treatment and prevention of erectile dysfunction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURCHARDT M ET AL: "Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans", BIOLOGY OF REPRODUCTION, SOCIETY FOR THE STUDY OF REPRODUCTION, CHAMPAIGN, IL, US, vol. 60, no. 2, February 1999 (1999-02-01), pages 398 - 404, XP002142278, ISSN: 0006-3363 *
LEE M-C ET AL: "THE EFFECT OF VASCULAR ENDOTHELIAL GROWTH FACTOR ON A RAT MODEL OF ARTERIAL IMPOTENCE", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 163, no. 4, SUPPL, April 2000 (2000-04-01), pages 198,AB877, XP001127486, ISSN: 0022-5347 *

Also Published As

Publication number Publication date
AU2001278981A1 (en) 2002-02-05
WO2002007757A2 (en) 2002-01-31
US20040180830A1 (en) 2004-09-16
US20020160951A1 (en) 2002-10-31
WO2002007757A9 (en) 2004-05-06
US6852323B2 (en) 2005-02-08
US7485311B2 (en) 2009-02-03
EP1365794A2 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
WO2002007757A3 (en) Prevention and treatment of sexual arousal disorders
WO2002047708A3 (en) Selective cox-2 inhibition from edible plant extracts
WO2002047706A3 (en) Selective cox-2 inhibition from plant extracts
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
WO2007070779A3 (en) A method to treat premature ejaculation in humans
WO1995017904A3 (en) Botulinum toxins for treating various disorders and associated pain
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2003045316A3 (en) Polynucleotide therapy
WO2001032926A3 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
TNSN04015A1 (en) Combination therapy for the treatment of cancer
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
WO2004066990A3 (en) Methods of treating lower urinary tract disorders using sodium channel modulators
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
BR0014166A (en) Method of using rapid attack selective serotonin reabsorption inhibitors to treat sexual dysfunction
WO2002009683A3 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
BR0203886A (en) Treatment methods and kits comprising a growth hormone secretagogue
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2003001968A3 (en) Compositions and methods for inhibiting platelet activation and thrombosis
ZA200405439B (en) Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders.
WO2004043365A3 (en) Method for treatment of premature ejaculation in humans
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001957212

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001957212

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGE 56, DESCRIPTION, REPLACED BY CORRECT PAGE 56

NENP Non-entry into the national phase

Ref country code: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)